Pharmaceutical company Upsher-Smith Laboratories LLC reported on Friday the availability of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg in the US.
The company said the Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg is an AA-rated generic version of the branded product, Lomotil (diphenoxylate hydrochloride and atropine sulfate tablets). Lomotil is a registered trademark of GD Searle LLC and the combination prescription drug is used to treat the symptoms of acute or chronic diarrhea.
For the 12 months ending May 2018, the diphenoxylate hydrochloride and atropine sulfate tablet market had US sales of approximately USD64m, according to IQVIA.
In conjunction, Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP are classified as a Schedule V controlled substance.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream